Form 4: Foghorn Therapeutics' Chief Scientific Officer Sells 20,000 Shares

Steven F. Bellon, Chief Scientific Officer of Foghorn Therapeutics, sold 20,000 shares of common stock at $9.50 per share on September 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 9, 2024, Steven F. Bellon, the Chief Scientific Officer of Foghorn Therapeutics Inc. (FHTX), sold 20,000 shares of the company's common stock.
• The sale was executed at a price of $9.50 per share.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2024.
• Following the transaction, Bellon directly owns 101,957 shares of Foghorn Therapeutics.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. The sale could be for personal financial reasons and doesn't necessarily reflect a negative view of the company.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It provides transparency into the transactions of company executives and their holdings in the company. Investors often monitor these filings to gain insights into management's perspective on the company's stock.

Stakeholder Impact

• The stock sale by a high-ranking officer could potentially create uncertainty among shareholders, although the existence of a pre-arranged trading plan mitigates this concern.

Key Dates